Klinische studies klein lymfocytair lymfoom (SLL)

Onbehandelde patiënten

Momenteel geen actieve studies.

Behandelde patiënten

HOVON 159

A prospective, multicenter, phase-II trial of venetoclax plus acalabrutinib in patients who have relapsed after first line venetoclax + anti-CD20 mAb treatment for chronic lymphocytic leukemia (CLL or SLL)

• Principal investigator: Prof. Dr. Ann Janssens
• More information: Hovon 159
• Internal reference number: S64626

J2N-MC-JZNX

A phase 2, open label, randomized study evaluating the efficacy and safety of 3 doses of pirtobrutinib in participants with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who previously received treatment with a covalent bruton tyrosine kinase inhibitor.

• Principal investigator: Prof. Dr. Ann Janssens
• More information: NCT06588478
• Internal reference number: S69650